Aduro BioTech Inc (ADRO) Holdings Lifted by Dimensional Fund Advisors LP

Share on StockTwits

Dimensional Fund Advisors LP raised its position in shares of Aduro BioTech Inc (NASDAQ:ADRO) by 143.9% during the 2nd quarter, HoldingsChannel reports. The fund owned 62,017 shares of the biotechnology company’s stock after purchasing an additional 36,588 shares during the period. Dimensional Fund Advisors LP’s holdings in Aduro BioTech were worth $434,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Legal & General Group Plc raised its holdings in shares of Aduro BioTech by 105.3% during the 1st quarter. Legal & General Group Plc now owns 22,233 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 11,405 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Aduro BioTech by 52.2% during the 2nd quarter. Rhumbline Advisers now owns 60,733 shares of the biotechnology company’s stock worth $425,000 after acquiring an additional 20,821 shares in the last quarter. Swiss National Bank raised its holdings in shares of Aduro BioTech by 27.5% during the 2nd quarter. Swiss National Bank now owns 73,300 shares of the biotechnology company’s stock worth $513,000 after acquiring an additional 15,800 shares in the last quarter. Wilbanks Smith & Thomas Asset Management LLC raised its holdings in shares of Aduro BioTech by 150.2% during the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 83,670 shares of the biotechnology company’s stock worth $586,000 after acquiring an additional 50,230 shares in the last quarter. Finally, Alps Advisors Inc. raised its holdings in shares of Aduro BioTech by 14.2% during the 2nd quarter. Alps Advisors Inc. now owns 114,257 shares of the biotechnology company’s stock worth $800,000 after acquiring an additional 14,187 shares in the last quarter. 48.17% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have recently issued reports on ADRO. Oppenheimer set a $10.00 price objective on Aduro BioTech and gave the stock a “buy” rating in a report on Tuesday. ValuEngine upgraded Aduro BioTech from a “sell” rating to a “hold” rating in a report on Monday, October 22nd. BidaskClub lowered Aduro BioTech from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. William Blair restated a “buy” rating on shares of Aduro BioTech in a report on Wednesday, October 3rd. Finally, HC Wainwright set a $8.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Tuesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $12.83.

NASDAQ:ADRO opened at $4.24 on Thursday. Aduro BioTech Inc has a fifty-two week low of $3.69 and a fifty-two week high of $10.00. The firm has a market cap of $351.82 million, a P/E ratio of -2.99 and a beta of 2.22.

Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings results on Tuesday, October 30th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.02. Aduro BioTech had a negative return on equity of 44.97% and a negative net margin of 574.11%. The company had revenue of $3.06 million for the quarter, compared to analyst estimates of $4.59 million. As a group, equities analysts forecast that Aduro BioTech Inc will post -1.24 earnings per share for the current fiscal year.

In other Aduro BioTech news, insider Stephen T. Isaacs sold 62,572 shares of the company’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $7.91, for a total value of $494,944.52. Following the transaction, the insider now owns 221,331 shares of the company’s stock, valued at approximately $1,750,728.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jennifer Lew sold 5,623 shares of the company’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.50, for a total value of $36,549.50. Following the completion of the transaction, the chief financial officer now directly owns 141,813 shares in the company, valued at approximately $921,784.50. The disclosure for this sale can be found here. Insiders have sold a total of 113,160 shares of company stock worth $819,523 in the last 90 days. 5.00% of the stock is currently owned by insiders.

Aduro BioTech Company Profile

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

See Also: How a Put Option Works

Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro BioTech Inc (NASDAQ:ADRO).

Institutional Ownership by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply